11.15.11FibroGen Reports Dose-finding Data from Phase 2b Study of FG-4592 for Anemia Correction and Maintenance in Chronic Kidney Disease Patients
9.12.11FibroGen Appoints Michael Martinelli, Ph.D., Vice President of Technical Development
6.6.11FibroGen Appoints R. Wayne Frost, Pharm.D., J.D., Vice President of Regulatory Affairs
5.3.11FibroGen Reports Proof-of-Principle for Oral Anemia Therapy FG-4592 in Hemodialysis Patients Switched from Intravenous rhEPO in an Active-Controlled Randomized Phase 2 Study
3.17.11FibroGen Announces Initiation of Phase 2b Studies of FG-4592, an Oral HIF Prolyl Hydroxylase Inhibitor, for Treatment of Anemia in Chronic Kidney Disease
1.21.11FibroGen Reports Interim Results of a Phase 1 / 2 Trial of FG-3019 in Locally Advanced or Metastatic Pancreatic Cancer
1.12.11FibroGen Announces the Initiation of an Open-label Phase 2 Study to Evaluate the Safety and Efficacy of FG-3019 in Individuals with Idiopathic Pulmonary Fibrosis
